Published in Gene Therapy Weekly, August 7th, 1995
Current methods for detecting early prostate cancer lack sensitivity and specificity. Physical exams might easily miss small or centrally located tumors; serum prostate-specific antigen (PSA) determination is not specific to malignant prostate disease; and tissue biopsy may lead to erroneous benign diagnosis through sampling error. Current techniques for early prediction/detection of therapeutic relapse are unsatisfactory as they require fairly bulky tumor regrowth before discovery.
Ruoquian Shen et al. cloned and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly